Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | FPR1 | P21462 | 2/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267160 | 0.84 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL5274407 | 0.84 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL2948885 | 0.83 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL3204569 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL9070 | 0.81 | ALDH1A1 (0.80) | ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL30991582 | 0.79 | ALDH1A1 (0.71) | ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL2946452 | 0.79 | ALDH1A1 (0.71) | ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL5270355 | 0.78 | KDM4E (0.65) | ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL28514417 | 0.76 | ALDH1A1 (0.63) | ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL13692850 | 0.74 | MAPT (0.80) | ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | US | disclosed |
| US-9718793-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LTD. (GB) | 2017-08-01 | — | — | US | disclosed |
| US-9718793-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LTD. (GB) | 2017-08-01 | — | — | US | disclosed |
| US-9718793-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LTD. (GB) | 2017-08-01 | — | — | US | disclosed |
| US-7705027-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| US-7705027-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| EP-1456180-B1 | 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE | VERNALIS CAMBRIDGE LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-7247734-B2 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-07-24 | — | — | US | disclosed |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS DEVELOPMENT LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1611112-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | Vernalis (Cambridge) Limited (GB) | 2006-01-04 | — | — | EP | disclosed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| EP-1456180-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | Vernalis (Oxford) Ltd (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004072051-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| WO-2003055860-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326152-A1 | Isoxazole Compounds As Inhibitors Of Heat Shock Proteins | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 350/4885CYP1A2 701/4885CYP2C9 1533/4885 |
| US-20060241106-A1 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 380/4885CYP1A2 875/4885CYP2C9 1799/4885 |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 351/4885CYP1A2 700/4885CYP2C9 1538/4885 |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 350/4885CYP1A2 701/4885CYP2C9 1533/4885 |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 986/4885CYP1A2 647/4885CYP2C9 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.